Published in Drug Week, June 11th, 2004
"In 2003 we received the strongest validation to date for our proprietary ACE System technology, as we signed our first commercial manufacturing deal in cellular protein production," said Alistair Duncan, president and CEO of Chromos. "This deal with Cambridge Antibody Technology was a milestone achievement that demonstrates the market's growing acceptance of our technology and proves its commercial viability. As the market potential of the ACE System's use in cellular protein production is realized, anticipated revenues from out-licensing deals will...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.